Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (OP: BVAXF )

0.0628 +0.0062 (+10.95%)
Streaming Delayed Price Updated: 2:47 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,563
Open 0.0575
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0566
Today's Range 0.0538 - 0.0628
52wk Range 0.0091 - 0.0758
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run... 
Via FinancialNewsMedia

Performance

YTD
+62.69%
+62.69%
1 Month
+4.67%
+4.67%
3 Month
+65.26%
+65.26%
6 Month
+398.41%
+398.41%
1 Year
+83.09%
+83.09%

More News

Read More
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Via FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
Via FinancialNewsMedia
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Via FinancialNewsMedia
Topics Death
Exposures Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
Via FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
Via FinancialNewsMedia
Exposures COVID-19
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
Via FinancialNewsMedia
Exposures COVID-19
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Via FinancialNewsMedia
Exposures COVID-19
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE
Via FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
Via FinancialNewsMedia
Exposures COVID-19
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
Via FinancialNewsMedia
Topics Death
Exposures COVID-19 Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
Via FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
Via FinancialNewsMedia
Exposures COVID-19
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Via FinancialNewsMedia
Exposures COVID-19
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
Via FinancialNewsMedia
Exposures COVID-19
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
Via FinancialNewsMedia
Exposures COVID-19
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
Via FinancialNewsMedia
Exposures COVID-19
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION
Via FinancialNewsMedia
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Exposures COVID-19
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.